Literature DB >> 26026095

Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis.

Irmina Grzegorek1, Dido Lenze2, Mariusz Chabowski3, Dariusz Janczak3, Małgorzata Szolkowska4, Renata Langfort4, Andrzej Szuba5, Piotr Dziegiel6.   

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease characterized by abnormal smooth muscle-like cell (LAM cell) proliferation in the lung stroma. The origin of LAM cells is still unknown. The gold-standard immunohistochemical diagnostic for LAM is an immunopositive reaction to the HMB-45 antibody.
MATERIALS AND METHODS: We aimed to evaluate 15 diagnostic open-lung biopsy specimens of pulmonary LAM. Based on the LAM histologic score (LHS), we distinguished two groups of histological severity: early- and advanced-stage LAM. The expression of HMB-45, estrogen receptor (ER), progesterone receptor (PR), β-catenin, E-cadherin, podoplanin (D2-40), mini-chromosome maintenance protein 3 (MCM3), and epidermal growth factor receptor (EGFR) was evaluated immunohistochemically. Fluorescence in situ hybridization (FISH) was performed in order to investigate amplification of the EGFR gene in LAM cells.
RESULTS: The expression of ER and EGFR was significantly higher in advanced than in early-stage LAM. Amplification of the EGFR gene was not detected in any of the 15 studied cases. There was a strong-positive correlation between the expression of PR, ER, β-catenin, E-cadherin, and the standard marker of LAM, HMB45.
CONCLUSION: We conclude that together with LHS, ER may be considered a useful tool for evaluating the progression of LAM. β-Catenin and E-cadherin seem to be new potential specific markers of LAM cells. The increased expression of EGFR in LAM cells is not associated with EGFR gene amplification, although it may be a marker of disease progression; the role of this receptor in LAM pathogenesis should be further investigated. Positive reaction of LAM cells with podoplain demonstrates the existence of an additional lymphatic endothelial lineage in LAM cells. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  E-cadherin; EGFR; Lymphangioleiomyomatosis; podoplanin; β-catenin

Mesh:

Substances:

Year:  2015        PMID: 26026095

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 2.  [Non-neoplastic lesions of the mediastinum].

Authors:  A Tzankov
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

3.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

4.  Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.

Authors:  Fei Han; Emilia R Dellacecca; Levi W Barse; Cormac Cosgrove; Steven W Henning; Christian M Ankney; Dinesh Jaishankar; Alexander Yemelyanov; Vera P Krymskaya; Daniel F Dilling; I Caroline Le Poole
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

5.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

6.  Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment.

Authors:  Yi Liu; Zhibin Guo; Chenlong Zhao; Xin Li; Hongyu Liu; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-08-31       Impact factor: 4.147

7.  Difficult diagnosis and rare morphology of lymphangioleiomyomatosis with giant cysts.

Authors:  Stefan Welter; Philipp Thrull; Michael Westhoff; Peter Bach; Helmut Popper; Hans-Jörg Maschek
Journal:  Respir Med Case Rep       Date:  2019-06-09

8.  Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer.

Authors:  Mark Kriegsmann; Katharina Kriegsmann; Alexander Harms; Rémi Longuespée; Christiane Zgorzelski; Jonas Leichsenring; Thomas Muley; Hauke Winter; Daniel Kazdal; Benjamin Goeppert; Arne Warth
Journal:  Diagn Pathol       Date:  2018-09-11       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.